Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 3
2007 2
2008 3
2009 19
2010 7
2011 1
2019 1
2020 2
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
Ducreux M, Tabernero J, Grothey A, Arnold D, O'Dwyer PJ, Gilberg F, Abbas A, Thakur MD, Prizant H, Irahara N, Tahiri A, Schmoll HJ, Van Cutsem E, de Gramont A. Ducreux M, et al. Among authors: irahara n. Eur J Cancer. 2023 May;184:137-150. doi: 10.1016/j.ejca.2023.01.023. Epub 2023 Feb 4. Eur J Cancer. 2023. PMID: 36921494 Free article. Clinical Trial.
A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors.
Oza AM, Dubois F, Hegg R, Hernández CA, Finocchiaro G, Ghiringhelli F, Zamagni C, Nick S, Irahara N, Perretti T, Colombo N. Oza AM, et al. Among authors: irahara n. Oncologist. 2021 Dec;26(12):e2254-e2264. doi: 10.1002/onco.13971. Epub 2021 Oct 4. Oncologist. 2021. PMID: 34498344 Free PMC article. Clinical Trial.
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer.
Tabernero J, Grothey A, Arnold D, de Gramont A, Ducreux M, O'Dwyer P, Tahiri A, Gilberg F, Irahara N, Schmoll HJ, Van Cutsem E. Tabernero J, et al. Among authors: irahara n. ESMO Open. 2022 Oct;7(5):100559. doi: 10.1016/j.esmoop.2022.100559. Epub 2022 Aug 24. ESMO Open. 2022. PMID: 36029653 Free PMC article. Clinical Trial.
NRAS mutations are rare in colorectal cancer.
Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S. Irahara N, et al. Diagn Mol Pathol. 2010 Sep;19(3):157-63. doi: 10.1097/PDM.0b013e3181c93fd1. Diagn Mol Pathol. 2010. PMID: 20736745 Free PMC article.
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N, Donica M, Lindegger N, Barrios CH. Montemurro F, et al. Among authors: irahara n. Eur J Cancer. 2019 Mar;109:92-102. doi: 10.1016/j.ejca.2018.12.022. Epub 2019 Jan 29. Eur J Cancer. 2019. PMID: 30708264 Free article. Clinical Trial.
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Redondo A, Colombo N, McCormack M, Dreosti L, Nogueira-Rodrigues A, Scambia G, Lorusso D, Joly F, Schenker M, Ruff P, Estevez-Diz M, Irahara N, Donica M, Gonzalez-Martín A. Redondo A, et al. Among authors: irahara n. Gynecol Oncol. 2020 Oct;159(1):142-149. doi: 10.1016/j.ygyno.2020.07.026. Epub 2020 Aug 4. Gynecol Oncol. 2020. PMID: 32763109 Clinical Trial.
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani RA, Fuchs CS, Ogino S. Baba Y, et al. Among authors: irahara n. Clin Cancer Res. 2009 Jul 15;15(14):4665-73. doi: 10.1158/1078-0432.CCR-09-0401. Epub 2009 Jul 7. Clin Cancer Res. 2009. PMID: 19584150 Free PMC article.
39 results